Shelly Heimfeld

powered by
COS Expertise®
Fred Hutchinson Cancer Research Center
Associate Member
Fred Hutchinson Cancer Research Center
Clinical Research
Cellular Therapy Laboratory and cGMP Cell Processing Facility
Director
Professional Headshot of Shelly Heimfeld

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. North, MS D5-390
P.O. Box 19024
Seattle, Washington 98109-1024
United States

Contact Information

Phone: (206) 667-4004
Fax: (206) 667-4937
sheimfel@fhcrc.org

Qualifications

Ph.D., University of California, Irvine, Cell Differentiation, 1983.

Expertise and Research Interests

The Cellular Therapy Laboratory is responsible for hematopoietic progenitor cell banking at the Fred Hutchinson Cancer Research Center. As Laboratory Director I have overall responsibility for the cell processing, cryopreservation, thawing, and infusion of all blood and bone marrow components used in the treatment of patients at the Center. My primary responsibility as Director is to ensure the safety, quality, and appropriateness of all blood or marrow-derived components used at this Center.

The Cellular Therapy Laboratory includes cell processing, cryopreservation, thawing and re-infusion of bone marrow and peripheral blood stem cell components used in the Fred Hutchinson Cancer Research Center transplant program.

Other Expertise

1999-2004 Co-Principal Investigator, NIH P30 Grant (DK56465-01), Core Center of Excellence in Molecular Hematology, Fred Hutchinson Cancer Research Center, Seattle, WA.

2000-2005 Director, Subproject Core D, NIH P50 Grant (HL54881-05), Biology of Hematopoietic Stem Cells, Fred Hutchinson Cancer Research Center, Seattle, WA.

2000-2006 Director, Subproject Core G, NIH PO1 Grant (CA18029-25), Adult Leukemia Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA.

2000-2004 Director,Subproject Core B, NIH P30 Grant (CA15704-27), Cancer Center Support, Fred Hutchinson Cancer Research Center, Seattle, WA.

Future Research

I have a broad range of research interests, with a particular focus on the development of improved therapeutic strategies using various human stem cell populations. My long-term goals for this area are to identify better markers for the characterization of stem and progenitor cells, to improve the isolation technologies for enriching these types of cells, and to develop ex-vivo manipulation strategies that can enhance the therapeutic potential of these cells.

Another primary research area will involve studying human dendritic cell populations. I am interested in exploring the differential mobilization of distinct dendritic precursor subsets in response to specific manipulations such as cytokine treatment, the identification of unique markers to enrich those types of cells, and the ex-vivo generation of dendritic cells from precursor populations. These dendritic cells will then be manipulated to either enhance specific immune responses (e.g. anti-tumor or anti-viral activity) or dampen down inappropriate reactions (e.g. GVHD, automimmune disease, tolerance induction).

All of these research goals have a therapeutic clinical focus, and will ultimately involve the 'engineering' of patient grafts to investigate the role of specific cell populations in transplantation outcomes. This ties in directly with the Center's Cellular Therapy Laboratory and the new cGMP facility, and the role these units will play in manipulating blood and bone marrow components for the treatment of patients. It has become clear that the FDA is becoming more involved in overseeing this area of graft engineering and intends to tightly regulate this field. Thus, another goal of mine is to become very proficient in GLP, GTP and GMP regulations, both to help the Center moveforward in the development of its therapeutic strategies, and to facilitate the interactions with the FDA in this rapidly evolving area.

Keywords

COS Keywords:

Cell Differentiation, Gene Therapy, Oncology, Stem Cells.

Additional Terms:

CGMP, Cell Selection, Cellular Therapy, Dendritic Cells, Gene Therapy, Graft Engineering, Stem Cells.

Languages

(Reading, Writing, Speaking)

English: (Fluent, Fluent, Fluent)

Memberships

American Association for the Advancement of Science
American Society for Blood and Bone Marrow Transplantation
American Society of Gene Therapy
European Hematology Association
International Cytokine Society
International Society for Experimental Hematology
International Society for Hematotherapy and Graft Engineering
New York Academy of Sciences

Honors and Awards

1986-1988, Postdoctoral Fellowship, Leukemia Society, Stanford University

Previous Positions

1988-1990, Co-Principal Investigator, SyStemix, Palo Alto, CA

Patents

Methods and Devises for Culturing Human Hematopoietic Cells and Their Precursors, Patent Number: 5635387, 1997, Self-owned, United States of America.
Apparatus and Method for Particle Separation in a Closed Field, Patent Number: 5672481, 1997, Self-owned, United States of America.
Homogeneous Mammalian Hematopoietic Stem Cell Composition, Patent Number: 5087570, 1992, Self-owned, United States of America.

Publications

  • Heimfeld S, Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation?, Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.k., 17(5), 856-8, May 2003 Abstract
  • Heimfeld, HLA-identical Stem Cell Transplantation: Is there an optimal CD34 cell dose?, Bone Marrow Transplantation, 31, 839-845, 2003
  • Heimfeld S, Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation?, Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K., 17(5), 856-8, 2003
  • Berger C, Blau A, Clackson T, Riddell S, Heimfeld S., CD28 costimulation and immunoaffinity-based selection efficiently generate gene-modified T cells for adoptive immunotherapy, Blood, 89 (2), 476-484, 2002
  • Rowley SD, Yu J, Gooley T, Heimfeld S, Holmberg L, Maloney D, Bensinger WI, Trafficking of CD34+ cells into the peripheral circulation during collection of peripheral blood stem cells by apheresis, Bone Marrow Transplantation, 28(7), 649-56, October 2001 Abstract
  • Zaucha JM, Gooley T, Bensinger WI, Heimfeld S et al., CD34 cell dose in g-csf-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-ide, Blood, 98(12), 3221-3227, 2001
  • Rowley SD, Yu J, Gooley T, Heimfeld S, et al, Trafficking of CD34+cells into the peripheral circulation during collection of peripheral blood stem cells by apheresis, Bone Marrow Transplantation, 28, 649-656, 2001
  • Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, Kashyap A, Flowers ME, Lilleby K, Chauncey TR, Storb R, Appelbaum FR, Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers, The New England Journal of Medicine, 344(3), 175-81, Jan 2001 Abstract
  • Graf L, Heimfeld S, Torok-Storb B, Comparison of gene expression in CD34+ cells from bone marrow and G-CSF-mobilized peripheral blood by high-density oligonucleotide array analysis, Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation., 7(9), 486-94, 2001 Abstract
  • Goerner M, Roecklein B, Torok-Storb B, Heimfeld S, Kiem HP, Expansion and transduction of nonenriched human cord blood cells using HS-5 conditioned medium and FLT3-L, Journal of Hematotherapy and Stem Cell Research, 9(5), 759-65, October 2000 Abstract
  • Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C, Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells, Blood, 95(8), 2484-90, 2000 Abstract
  • Yu J, Leisenring W, Fritschle W, Heimfeld S, Shulman H, Bensinger WI, Holmberg LA, Rowley SD, Enumeration of HPC in mobilized peripheral blood with the Sysmex SE9500 predicts final CD34 cell yield in the apheresis collection, Bone Marrow Transplantation, 25(11), 1157-64, 2000
  • Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S, Press O, Maloney DG, McSweeney P, Corey L, Maziarz RT, Appelbaum FR, Bensinger W, Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation, Blood, 94(12), 4029-35, 1999 Abstract
  • Yin LH, Fu SQ, Nanakorn T, Garcia-Sanchez F, Chung I, Cote R, Pizzorno G, Hanania E, Heimfeld S, Crystal R, Deisseroth A, Results of retroviral and adenoviral approaches to cancer gene therapy, Stem Cells, 16 Suppl 1, 247-50, 1998 Abstract
  • Shapiro F, Yao TJ, Moskowitz C, Reich L, Wuest DL, Heimfeld S, McNiece IK, Gabrilove J, Nimer S, Moore MA, Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells, Clinical Cancer Research, 3(9), 1571-8, 1997
  • Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB, BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients, Blood, 87(11), 4770-9, 1996 Abstract
  • Heslop HE, Brenner MK, Krance RA, Bowman L, Cunningham JM, Richardson S, Alexander B, Heideman R, Boyett JM, Srivastava DK, Marcus SG, Berenson R, Heimfeld S, Brown S, Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34 selected marrow cells in patients undergoing autologous bone marrow transplan, Human Gene Therapy, 7(5), 655-67, 1996 Abstract
  • Berenson RJ, Shpall EJ, Auditore-Hargreaves K, Heimfeld S, Jacobs C, Krieger MS, Transplantation of CD34 hematopoietic progenitor cells, Cancer Investigation, 14(6), 589-96, 1996 Abstract
  • Colter M, Jones M, Heimfeld S, CD34 progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing, Journal of Hematotherapy, 5(2), 179-84, 1996
  • Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L, Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo, New England Journal of Medicine, 333(5), 283-7, 1995 Abstract
  • Brugger W, Henschler R, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L, Positively selected autologous blood CD34 cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirub, Blood, 84(5), 1421-6, 1994 Abstract
  • Ruggieri L, Heimfeld S, Broxmeyer HE, Cytokine-dependent ex vivo expansion of early subsets of CD34 cord blood myeloid progenitors is enhanced by cord blood plasma, but expansion of the more mature subsets of progenitors is favored, Blood Cells, 20(2-3), 436-54, 1994 Abstract
  • Heimfeld S, Kalamasz DF, Fogarty BL, Fei R, Tsui ZN, Jones HM, Berenson RJ, Isolation and ex vivo expansion of CD34 cells from cord blood using dextran sedimentation and avidin column selection, Blood Cells, 20(2-3), 397-403, 1994 Abstract

Profile Details

Last Updated: 7/2/2003

COS Expertise ID #345992
Reference this profile directly: http://myprofile.cos.com/Heimfeld